BioStem Technologies

BioStem Technologies BioStem Technologies is a leading manufacturer and distributor of superior perinatal tissue products

In our AATB® accredited, FDA registered, cGMP compliant lab, we strive to provide products and services which not only meet but exceed, Current Good Tissue Practice requirements.

September is Urology Awareness Month! 💙Every year, September shines a vital spotlight on urology health—raising awarenes...
09/04/2026

September is Urology Awareness Month! 💙

Every year, September shines a vital spotlight on urology health—raising awareness for both urological cancers and benign conditions like incontinence and kidney stones.

The theme for Urology Awareness Month 2026 is "Worth its weight in GOLD!" At BioStem Technologies, we are proud to support the dedicated urology community to deliver gold-standard patient care.

👉 Medical professionals: How are you raising awareness or advancing care this month? Email us at [email protected] if you're interested in learning more about the use of our allografts for surgical site protection in urologic care.

BioStem Technologies is heading to Tucson for the 105th Annual Meeting of the South Central Section of the American Urol...
09/02/2026

BioStem Technologies is heading to Tucson for the 105th Annual Meeting of the South Central Section of the American Urological Association!

Join us September 9–12 as we connect with urology professionals, exchange clinical insights, and share how our placental allograft portfolio supports physicians across a range of surgical applications.

If you’re attending, stop by our exhibit to meet the BioStem team and learn more about the science behind our innovative allograft solutions.

📍 JW Marriott Tucson Starr Pass Resort & Spa
📅 September 9–12, 2026

Learn more: https://hubs.ly/Q04vHF-Q0

🏆 We’ve Got Moxie!We’re proud to announce that BioStem Technologies is a 2026 Moxie Award South Florida finalist!The Mox...
08/26/2026

🏆 We’ve Got Moxie!

We’re proud to announce that BioStem Technologies is a 2026 Moxie Award South Florida finalist!

The Moxie Award celebrates organizations that embody boldness in business—companies that innovate, challenge the status quo, take smart risks, and make a meaningful impact.

That spirit is at the heart of BioStem.

Every day, our team is driven to push the boundaries of regenerative medicine through scientific innovation, advanced processing technologies, and an unwavering commitment to improving patients’ lives.

This nomination is a reflection of the passion, determination, and "moxie" of the entire BioStem team—and we couldn’t be prouder.

Thank you Moxie Award South Florida for this recognition. We’re honored to be among the bold organizations helping shape the future of business and innovation in South Florida.

Bold ideas. Bold technology. Bold future. That’s BioStem.

🌐 A New Look for a New Chapter at BioStem Technologies.We’re excited to unveil the newly redesigned BioStem Technologies...
08/13/2026

🌐 A New Look for a New Chapter at BioStem Technologies.

We’re excited to unveil the newly redesigned BioStem Technologies website—built to better reflect who we are today and where we’re headed.

Explore our expanded portfolio of advanced perinatal tissue allografts, including Clarix® and Neox®, alongside our VENDAJE® and American Amnion® wound care solutions.

Discover the science and innovation behind our three proprietary processing technologies:
CryoTek®
SteriTek®
BioRetain®

From advanced wound care to surgical applications, our new website brings our products, technologies, clinical evidence, and commitment to innovation together in one place.

New look. Expanded portfolio. One BioStem.
Visit https://hubs.ly/Q04sTR6m0 and explore what’s new.

Building Momentum. Delivering Growth. Advancing BioStem.BioStem Technologies (Nasdaq: BSEM) has announced its Second Qua...
08/12/2026

Building Momentum. Delivering Growth. Advancing BioStem.

BioStem Technologies (Nasdaq: BSEM) has announced its Second Quarter 2026 financial results, reflecting continued progress across our business and another important step forward in our growth strategy.

Key Q2 highlights include:
🔹 $7.9 million in net revenue — a 29% sequential increase from Q1 2026
🔹 $6.7 million in hospital revenue as we continue expanding our presence across hospital systems nationwide
🔹 Raised full-year 2026 revenue guidance to $26–$29 million
🔹 Continued expansion of our commercial organization and infrastructure
🔹 Eight new U.S. design patents strengthening our intellectual property portfolio
🔹 And a major company milestone: our successful uplisting to the Nasdaq Capital Market

As we continue to integrate our expanded portfolio, strengthen our commercial platform, and broaden access to our innovative perinatal tissue allograft solutions, we’re excited about what lies ahead. The foundation is stronger. The reach is growing. And BioStem is just getting started.

Read the full Q2 2026 financial results: Press Release https://hubs.ly/Q04sQFss0

Join us on today, August 12 at 4:30 PM ET as BioStem Technologies® hosts our Second Quarter 2026 Financial Results Confe...
08/12/2026

Join us on today, August 12 at 4:30 PM ET as BioStem Technologies® hosts our Second Quarter 2026 Financial Results Conference Call and Webcast.

Our management team will provide an update on the quarter and discuss the Company's continued progress.
📅 August 12, 2026
🕟 4:30 PM ET
Register for the live webcast here: https://hubs.ly/Q04sQnqX0

🎉 First Trade!Today marks a defining moment in BioStem Technologies®' history.We are proud to announce that BioStem Tech...
08/07/2026

🎉 First Trade!

Today marks a defining moment in BioStem Technologies®' history.

We are proud to announce that BioStem Technologies is now trading on the Nasdaq Capital Market under the ticker: BSEM.

Our first trade on Nasdaq represents more than a listing—it reflects years of innovation, growth, and an unwavering commitment to advancing regenerative medicine through the development of transformative perinatal tissue allografts.

To our employees, physician partners, donors, shareholders, and everyone who has supported our journey—thank you. Your dedication and belief in our mission have helped make this milestone possible.

As we begin this exciting new chapter, our focus remains unchanged: delivering innovative technologies that improve patient outcomes while creating long-term value for our stakeholders.

Here's to the future. The journey continues.

Learn more about BioStem Technologies and our mission at https://hubs.ly/Q04scKZk0

🚀 A Milestone Moment for BioStem Technologies®We are proud to announce that BioStem Technologies has been approved for l...
08/06/2026

🚀 A Milestone Moment for BioStem Technologies®

We are proud to announce that BioStem Technologies has been approved for listing on the Nasdaq Capital Market. Beginning August 7, 2026, our common stock is expected to trade on Nasdaq under our existing ticker symbol: BSEM.

This achievement marks an important milestone in BioStem's journey and reflects our continued commitment to advancing regenerative medicine through the development, manufacturing, and commercialization of innovative perinatal tissue allograft solutions.

In connection with our Nasdaq listing, our Form 10 Registration Statement has become effective, further strengthening our position as a publicly reporting company under the Securities Exchange Act of 1934.

This milestone would not have been possible without the dedication of our employees, the trust of our physicians and partners, and the continued support of our shareholders. Thank you for being part of this exciting journey as we continue working to improve patient outcomes and drive innovation in regenerative medicine.

Learn more in today's press release and visit our Investor Relations page: https://hubs.ly/Q04sbJlr0

08/05/2026

We're excited to be exhibiting at the 2026 ACOG District XII Annual District Meeting in Orlando, August 7–9!

As leading OB/GYN physicians from across the region come together to explore the latest advancements in women's healthcare, we're proud to showcase how BioStem's placental tissue technologies are helping advance the future of regenerative medicine.

Throughout the meeting, attendees will engage in expert-led sessions covering:
🩺 Menopause, sexual health, and midlife care
🤰 Complex obstetric care and family planning
🔬 Screening, diagnostics, adolescent gynecology, and professional development

If you're attending, be sure to stop by the BioStem booth #399 to learn more about our innovative placental tissue solutions and meet our team.

We look forward to connecting with OB/GYN leaders dedicated to improving patient care.

📍 ACOG District XII Annual District Meeting
📅 August 7–9, 2026
🏨 Loews Royal Pacific Resort at Universal Orlando
📍Booth #399

Join us on Wednesday, August 12 at 4:30 PM ET as BioStem Technologies® hosts our Second Quarter 2026 Financial Results C...
07/29/2026

Join us on Wednesday, August 12 at 4:30 PM ET as BioStem Technologies® hosts our Second Quarter 2026 Financial Results Conference Call and Webcast.

Our management team will provide an update on the quarter and discuss the Company's continued progress.

📅 August 12, 2026
🕟 4:30 PM ET

Register for the live webcast here: https://hubs.ly/Q04rd6zq0

Address

2836 Center Port Cir
Pompano Beach, FL
33064

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+19543808342

Website

Alerts

Be the first to know and let us send you an email when BioStem Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BioStem Technologies:

Shortcuts

Share

Category